fluoxetine has been researched along with Phobic Disorders in 53 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Phobic Disorders: Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 9.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 9.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| "To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 5.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 5.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| " By the response of the patients to alprazolam (anxiolytic) and fluoketin (antidepressant) given by a special scheme, 3 types of comorbidity of obsessional-phobic and affective disturbances were recognized: 1) prevalent depression, 2) combination of dysthymia with marked obsessional-phobic disorders, 3) overcoming of obsessional-phobic and affective disorders." | 5.07 | [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. ( Andriushchenko, AV; Koliutskaia, EV; Morkovkina, IV; Smulevich, AB; Tkhostov, ASh, 1994) |
| "Relapse of major depressive disorder (MDD) is a common clinical problem." | 2.75 | Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. ( Baer, L; Chen, Y; Chuzi, S; Clain, A; Fava, M; Johnson, D; McGrath, PJ; Papakostas, GI; Sinicropi-Yao, L; Stewart, JW; Yang, H, 2010) |
| "Both fluoxetine and SET-C were more efficacious than placebo in reducing social distress and behavioral avoidance and increasing general functioning." | 2.73 | SET-C versus fluoxetine in the treatment of childhood social phobia. ( Ammerman, RT; Beidel, DC; Crosby, LA; Pathak, S; Sallee, FR; Turner, SM, 2007) |
| "Sixteen subjects with elective mutism were treated with placebo (single-blind) for 2 weeks." | 2.67 | Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. ( Black, B; Uhde, TW, 1994) |
| "Selective mutism is a communication disorder of childhood in which the child does not speak in specific social situations despite the ability to speak in other situations." | 2.44 | [Treatment of selective mutism]. ( Melfsen, S; Warnke, A, 2007) |
| "Excessive sweating (hyperhidrosis) is an overlooked and potentially disabling symptom, which is often seen in social anxiety disorder (SAD)." | 1.31 | Hyperhidrosis in social anxiety disorder. ( Churchill, LE; Connor, KM; Davidson, JR; Foa, EB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.77) | 18.7374 |
| 1990's | 26 (49.06) | 18.2507 |
| 2000's | 17 (32.08) | 29.6817 |
| 2010's | 8 (15.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlando, JM | 1 |
| Stepita, ME | 1 |
| Bain, MJ | 1 |
| Moesta, A | 1 |
| Vigne, P | 1 |
| de Menezes, GB | 1 |
| Yücel, M | 1 |
| Fontenelle, LF | 1 |
| Melvin, GA | 1 |
| Dudley, AL | 1 |
| Gordon, MS | 1 |
| Klimkeit, E | 1 |
| Gullone, E | 1 |
| Taffe, J | 1 |
| Tonge, BJ | 1 |
| Manassis, K | 1 |
| Tannock, R | 1 |
| Yang, H | 1 |
| Chuzi, S | 1 |
| Sinicropi-Yao, L | 1 |
| Johnson, D | 1 |
| Chen, Y | 1 |
| Clain, A | 1 |
| Baer, L | 1 |
| McGrath, PJ | 1 |
| Stewart, JW | 1 |
| Fava, M | 2 |
| Papakostas, GI | 1 |
| Alfano, CA | 2 |
| Pina, AA | 1 |
| Villalta, IK | 1 |
| Beidel, DC | 5 |
| Ammerman, RT | 3 |
| Crosby, LE | 1 |
| De Los Reyes, A | 1 |
| Scharfstein, LA | 1 |
| Finnell, LR | 1 |
| Distler, A | 1 |
| Carter, NT | 1 |
| Camacho, A | 1 |
| Stein, MB | 1 |
| Davidson, JR | 5 |
| Foa, EB | 3 |
| Connor, KM | 2 |
| Churchill, LE | 1 |
| Berger, I | 1 |
| Jaworowski, S | 1 |
| Gross-Tsur, V | 1 |
| Clark, DM | 2 |
| Ehlers, A | 1 |
| McManus, F | 2 |
| Hackmann, A | 2 |
| Fennell, M | 1 |
| Campbell, H | 1 |
| Flower, T | 1 |
| Davenport, C | 1 |
| Louis, B | 1 |
| Huppert, JD | 2 |
| Franklin, ME | 1 |
| Vorob'eva, OV | 1 |
| Vasil'chikova, NV | 1 |
| Clark, DB | 1 |
| Birmaher, B | 1 |
| Axelson, D | 1 |
| Monk, K | 1 |
| Kalas, C | 1 |
| Ehmann, M | 1 |
| Bridge, J | 1 |
| Wood, DS | 1 |
| Muthen, B | 1 |
| Brent, D | 1 |
| Leveleki, C | 1 |
| Sziray, N | 1 |
| Levay, G | 1 |
| Barsvári, B | 1 |
| Soproni, K | 1 |
| Mikics, E | 1 |
| Haller, J | 1 |
| Young, BJ | 1 |
| Turner, SM | 2 |
| McGraw, K | 1 |
| Coaston, SC | 1 |
| Vaishnavi, S | 1 |
| Sheehan, DV | 1 |
| Sheehan, KH | 1 |
| Strunk, DR | 1 |
| Ledley, DR | 1 |
| Sallee, FR | 1 |
| Crosby, LA | 1 |
| Pathak, S | 1 |
| Melfsen, S | 1 |
| Warnke, A | 1 |
| Phillips, KA | 1 |
| Atala, KD | 1 |
| Albertini, RS | 1 |
| Campbell, M | 1 |
| Cueva, JE | 1 |
| Motavalli, N | 1 |
| Berk, M | 1 |
| Smulevich, AB | 1 |
| Andriushchenko, AV | 1 |
| Morkovkina, IV | 1 |
| Tkhostov, ASh | 1 |
| Koliutskaia, EV | 1 |
| Black, B | 3 |
| Uhde, TW | 3 |
| Alpert, JE | 1 |
| Maddocks, A | 1 |
| Rosenbaum, JF | 1 |
| Marshall, RD | 1 |
| Schneier, FR | 4 |
| Fallon, BA | 2 |
| Feerick, J | 2 |
| Liebowitz, MR | 5 |
| Van Ameringen, M | 1 |
| Mancini, C | 1 |
| Streiner, DL | 1 |
| Miner, CM | 1 |
| Potts, NL | 1 |
| Tupler, LA | 1 |
| Charles, HC | 1 |
| Krishnan, KR | 1 |
| Jefferson, JW | 2 |
| Bohn, P | 1 |
| Sternbach, H | 2 |
| Taylor, LH | 1 |
| Fairbanks, JM | 1 |
| Pine, DS | 1 |
| Tancer, NK | 1 |
| Dummit, ES | 1 |
| Kentgen, LM | 1 |
| Martin, J | 1 |
| Asche, BK | 1 |
| Klein, RG | 1 |
| Heimann, SW | 1 |
| Pollack, MH | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Monasterio, E | 1 |
| Mulder, RT | 1 |
| Marshall, TD | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Rossi, A | 1 |
| Pazzagli, A | 1 |
| Kobak, KA | 1 |
| Greist, JH | 1 |
| Katzelnick, DJ | 1 |
| Carrasco, JL | 1 |
| Hollander, E | 3 |
| Tancer, ME | 1 |
| Chin, SJ | 1 |
| Zarzar, MN | 1 |
| Kingsley, RS | 1 |
| Welkowitz, LA | 1 |
| Saoud, JB | 1 |
| Campeas, R | 1 |
| Street, L | 1 |
| Gitow, A | 1 |
| Brady, K | 1 |
| Zarzar, M | 1 |
| Lydiard, RB | 1 |
| Gorman, JM | 1 |
| Dillon, D | 1 |
| Fyer, AJ | 1 |
| Cohen, BS | 1 |
| Klein, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Childhood Social Phobia[NCT00043537] | Phase 3 | 139 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol[NCT02659436] | 9 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD[NCT03993535] | Phase 4 | 250 participants (Actual) | Interventional | 2018-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fluoxetine and Phobic Disorders
| Article | Year |
|---|---|
Selective mutism: a review of the concept and treatment.
Topics: Anxiety; Fluoxetine; Humans; Monoamine Oxidase Inhibitors; Mutism; Phenelzine; Phobic Disorders; Pre | 2002 |
[Treatment of selective mutism].
Topics: Behavior Therapy; Child; Child, Preschool; Cognitive Behavioral Therapy; Combined Modality Therapy; | 2007 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
Medication therapy for social phobia.
Topics: Benzamides; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modali | 1994 |
Social phobia: everyone's disorder?
Topics: Adrenergic beta-Antagonists; Blushing; Clinical Trials as Topic; Clonazepam; Fluoxetine; Humans; Mon | 1996 |
20 trials available for fluoxetine and Phobic Disorders
| Article | Year |
|---|---|
Augmenting Cognitive Behavior Therapy for School Refusal with Fluoxetine: A Randomized Controlled Trial.
Topics: Adolescent; Adolescent Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fl | 2017 |
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adolescent; Adult; Aged; Checklist; Depressive Disorder, Major; Double-Blind Method; Drug Administra | 2010 |
Mediators and moderators of outcome in the behavioral treatment of childhood social phobia.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Behavior Therapy; Child; Female; Fluoxetine; H | 2009 |
The relations among measurements of informant discrepancies within a multisite trial of treatments for childhood social phobia.
Topics: Adolescent; Behavior Therapy; Child; Female; Fluoxetine; Humans; Male; Models, Psychological; Observ | 2010 |
Do pharmacological and behavioral interventions differentially affect treatment outcome for children with social phobia?
Topics: Adaptation, Psychological; Adolescent; Child; Combined Modality Therapy; Female; Fluoxetine; Humans; | 2011 |
Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Desensitization, Psychologic; Female | 2003 |
Study refusal and exclusion from a randomized treatment study of generalized social phobia.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Humans; Male; Pa | 2003 |
Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial.
Topics: Adolescent; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; Follow-Up Studies; Hu | 2005 |
Pretreatment attrition and childhood social phobia: Parental concerns about medication.
Topics: Adolescent; Attitude to Health; Behavior Therapy; Child; Female; Fluoxetine; Humans; Male; Parents; | 2006 |
Generalized social anxiety disorder and avoidant personality disorder: structural analysis and treatment outcome.
Topics: Activities of Daily Living; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbid | 2008 |
SET-C versus fluoxetine in the treatment of childhood social phobia.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Diagnostic and Statistical Manual of Mental Disorde | 2007 |
[The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)].
Topics: Adult; Alprazolam; Anxiety; Comorbidity; Depression; Double-Blind Method; Female; Fluoxetine; Humans | 1994 |
Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.
Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mutism; | 1994 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; | 1994 |
Fluoxetine efficacy in social phobia.
Topics: Adult; Age Factors; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; M | 1993 |
Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; | 1997 |
The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Fluoxeti | 1999 |
Recurrent images and early memories in social phobia.
Topics: Adult; Anxiety; Cognition; Cognitive Behavioral Therapy; Conditioning, Psychological; Eidetic Imager | 2000 |
Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Double-Blind Method; Female; Fluoxetine; Humans; M | 2002 |
Elective mutism as a variant of social phobia.
Topics: Child; Desipramine; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Mutism; Phobic Dis | 1992 |
28 other studies available for fluoxetine and Phobic Disorders
| Article | Year |
|---|---|
Animal Behavior Case of the Month.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal | 2017 |
Animal behavior case of the month. Noise phobia, cognitive dysfunction, separation anxiety, attention-seeking behavior, and medical causes.
Topics: Aggression; Alprazolam; Animals; Behavior, Animal; Dog Diseases; Dogs; Dose-Response Relationship, D | 2013 |
Animal behavior case of the month. Noise phobia.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Clorazepate Dipotassium; Dog Diseases; Dogs; Female; | 2014 |
Can hoarding be a symptom of social anxiety disorder? A case study.
Topics: Adult; Behavioral Symptoms; Fluoxetine; Hoarding Disorder; Humans; Interview, Psychological; Male; P | 2013 |
Comparing interventions for selective mutism: a pilot study.
Topics: Child; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Mutism; Perso | 2008 |
Modafinil for social phobia and amphetamine dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbidity; | 2002 |
Hyperhidrosis in social anxiety disorder.
Topics: Acetates; Adult; Amines; Calcium Channel Blockers; Clinical Trials as Topic; Clonazepam; Cognitive B | 2002 |
[The peculiarities of panic disorders determined by gender dimorphism].
Topics: Antidepressive Agents, Second-Generation; Beta Rhythm; Citalopram; Electroencephalography; Female; F | 2004 |
Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Buspirone; Chlordiazepoxide; Diazepam; Disea | 2006 |
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale.
Topics: Adult; Anti-Anxiety Agents; Clinical Trials as Topic; Clonazepam; Cross-Sectional Studies; Female; F | 2007 |
Case study: body dysmorphic disorder in adolescents.
Topics: Adolescent; Body Image; Depressive Disorder; Female; Fluoxetine; Humans; Male; Phobic Disorders; Psy | 1995 |
Fluoxetine for (s)elective mutism.
Topics: Adolescent; Child; Developing Countries; Female; Fluoxetine; Follow-Up Studies; Humans; Mutism; Phob | 1995 |
Fluoxetine and social phobia.
Topics: Adult; Bulimia; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Phobic Disorders | 1995 |
Practical approaches to the treatment of social phobia.
Topics: Adrenergic beta-Antagonists; Behavior Therapy; Benzamides; Benzodiazepines; Bupropion; Clonazepam; C | 1994 |
Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain Chemistry; Female; Fluorine Radioisotopes; Fl | 1995 |
Topical aluminum chloride for social phobia-related hyperhidrosis.
Topics: Administration, Topical; Aluminum Chloride; Aluminum Compounds; Astringents; Chlorides; Fluoxetine; | 1996 |
Fluoxetine efficacy in social phobia.
Topics: Adult; Drug Administration Schedule; Fluoxetine; Follow-Up Studies; Humans; Male; Phobic Disorders | 1997 |
SSRI for body dysmorphic disorder.
Topics: Adolescent; Body Image; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; H | 1997 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Obsessive-compulsive disorder in post-streptococcal infection.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Female; Fluoxetine; Humans; Hyg | 1998 |
Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
Topics: Adult; Clomipramine; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsess | 1992 |
Fluoxetine for the treatment of social phobia.
Topics: Adult; Female; Fluoxetine; Humans; Male; Phobic Disorders; Prognosis; Psychiatric Status Rating Scal | 1992 |
Fluoxetine in social phobia.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Phobic Disorders | 1992 |
Use of fluoxetine in a person with cardiac arrhythmias.
Topics: Cardiac Complexes, Premature; Depressive Disorder; Electrocardiography; Electrocardiography, Ambulat | 1990 |
Treatment of social phobia with drugs other than benzodiazepines.
Topics: Adolescent; Atenolol; Benzamides; Buspirone; Child; Clinical Trials as Topic; Female; Fluoxetine; Hu | 1991 |
Fluoxetine treatment of social phobia.
Topics: Adult; Fluoxetine; Humans; Male; Phobic Disorders; Social Adjustment; Social Environment | 1990 |
Fluoxetine in panic disorder patients with imipramine-associated weight gain.
Topics: Adult; Agoraphobia; Depressive Disorder; Fear; Female; Fluoxetine; Humans; Imipramine; Middle Aged; | 1989 |
Antipanic drug effects during lactate infusion in lactate-refractory panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Desipramine; Fear; Female; Fluoxetine; Humans; Imipramine | 1987 |